

NIHR CRSU

COMPLEX REVIEWS SUPPORT UNIT



University
of Glasgow



UNIVERSITY OF
LEICESTER

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



FUNDED BY
NIHR | National Institute
for Health Research

CRSU & Cochrane Workshop

22nd November 2019

GCU London

The Complex Reviews Support Unit (CRSU) is funded by the National Institute for Health Research
(project number 14/178/29)

Argumentation based synthesis: an illustrative example

Neil Hawkins PhD Cstat, University of Glasgow, UK

Argumentation based synthesis

Artificial Intelligence in Medicine 56 (2012) 173–190



Contents lists available at SciVerse ScienceDirect

Artificial Intelligence in Medicine

journal homepage: www.elsevier.com/locate/aiim



Aggregating evidence about the positive and negative effects of treatments

Anthony Hunter^{a,*}, Matthew Williams^b

^a Department of Computer Science, University College London, London WC1E 6BT, UK

^b Department of Clinical Oncology, University College Hospital, London NW1 2PG, UK

ARTICLE INFO

Article history:

Received 12 September 2011

Received in revised form

20 September 2012

Accepted 22 September 2012

Keywords:

Computational models of argument

Argument systems

Knowledge aggregation

Evidence aggregation

Evidence-based medicine

Clinical recommendations

ABSTRACT

Objectives: Evidence-based decision making is becoming increasingly important in healthcare. Much valuable evidence is in the form of the results from clinical trials that compare the relative merits of treatments. In this paper, we present a new framework for representing and synthesizing knowledge from clinical trials involving multiple outcome indicators.

Method: The framework generates and evaluates arguments for claiming that one treatment is superior, or equivalent, to another based on the available evidence. Evidence comes from randomized clinical trials, systematic reviews, meta-analyses, network analyses, etc. Preference criteria over arguments are used that are based on the outcome indicators, and the magnitude of those outcome indicators, in the evidence. Meta-arguments attacks arguments that are based on weaker evidence.

Results: We evaluated the framework with respect to the aggregation of evidence undertaken in three published clinical guidelines that involve 56 items of evidence and 16 treatments. For each of the three guidelines, the treatment we identified as being superior using our method is a recommended treatment in the corresponding guideline.

Conclusions: The framework offers a formal approach to aggregating clinical evidence, taking into account subjective criteria such as preferences over outcome indicators. In the evaluation, the aggregations obtained showed a good correspondence with published clinical guidelines. Furthermore, preliminary computational studies indicate that the approach is viable for the size of evidence tables normally encountered in practice.

© 2012 Elsevier B.V. All rights reserved.


Table of arguments

Table 1

Four results obtained from the NICE Hypertension Guideline (GC34, pages 36–37) concerning angiotensin-converting inhibitors (ACE) and calcium channel blockers (CCB).

	Left	Right	Outcome indicator	Value	Net	Sig	Type
e_1	ACE	CCB	Mortality	1.04	<	No	MA
e_2	ACE	CCB	Stroke	1.15	<	Yes	MA
e_3	ACE	CCB	Heart failure	0.84	>	Yes	MA
e_4	ACE	CCB	Diabetes	0.85	>	Yes	MA

Superiority Graph



1st Line Treatment for Chronic myelogenous Leukemia (CML)

- **CML** form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. Typically related to a specific mutation (Philadelphia chromosome)
- First Line Treatments
 - **Imatinib**
 - Bosutinib
 - **Nilotinib**
 - **Dasatinib**
- Effectiveness Endpoint
 - Major Molecular Remission (MMR)

Published NMA

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis

This article was published in the following Dove Press journal:
Cancer Management and Research

Kang-Kang Chen¹
Tai-Feng Du¹
Ku-Sheng Wu²
Wei Yang³

¹Department of Preventive Medicine and MPH Education Center, Shantou University Medical College, Shantou, Guangdong Province, China;

²Department of Preventive Medicine, Shantou University Medical College, Shantou, Guangdong Province, China;

³Department of Thoracic Surgery, Administrative Office, Shantou University Medical College Cancer Hospital, Shantou, Guangdong Province, China

Objectives: With bosutinib proven to be available for frontline treatment, there are currently four frontline treatments as well as an additional strategy with high-dose imatinib for newly diagnosed chronic myeloid leukemia (CML). Due to the lack of direct comparison of high-dose imatinib, dasatinib, nilotinib, and bosutinib, we summarized the evidence to indirectly compare the efficacy among these treatment options.



Methods: In total, 14 randomized clinical trials including 5,630 patients were analyzed by direct and mixed-treatment comparisons. Outcomes assessed were the following: complete cytogenetic response at 12 months; major molecular response at 12, 24, and 36 months; deep molecular response at 12, 24, 36, and 60 months; early molecular response at 3 months; progression-free survival (PFS); overall survival (OS); and Grade 3 or 4 adverse events (AEs).

Results: The Bayesian network meta-analysis demonstrated that high-dose imatinib was less effective than all new-generation tyrosine kinase inhibitors and had a higher probability of Grade 3 or 4 AEs. For molecular response, 300 mg of nilotinib was likely to be the preferred frontline treatment, as demonstrated by higher response rates and faster, deeper, and longer molecular response. For PFS and OS, there were high likelihoods (79% and 74%, respectively) that 400 mg of nilotinib was the preferred option. For AEs, standard-dose imatinib has the highest probability (65%) of being the most favorable toxicity profile.



Conclusion: Considering the efficacy and toxicity profile, it is not recommended to use high-dose imatinib for treatment. This analysis also showed that nilotinib has the highest probability to become the preferred frontline agents for treating CML.

Keywords: CML, tyrosine kinase inhibitor, imatinib, bosutinib, dasatinib, nilotinib

MMR at 12 Months



Grade 3 or 4 AEs



Patient information leaflet

STEP BY STEP

Chronic Myeloid
Leukaemia
(CML)



Comparison between treatments

●● Some of the side effects weren't nice; upset stomach, bone pains and tiredness. But as this drug was going to keep me alive, I was going to stick with it. ●●

Remember to mention any side effects you're experiencing to your healthcare team as they will be able to help manage them.


Side effect	Imatinib	Dasatinib	Nilotinib	Bosutinib	Ponatinib
Fatigue	More than 1 in 10 patients		More than 1 in 10 patients		More than 1 in 10 patients
Headache	More than 1 in 10 patients		More than 1 in 10 patients	More than 1 in 10 patients	More than 1 in 10 patients
Muscle/joint pain	More than half of all patients	More than 1 in 10 patients			More than 1 in 10 patients
Diarrhoea	More than 1 in 10 patients	More than 1 in 10 patients		More than half of all patients	
Nausea/vomiting	More than 1 in 10 patients	More than 1 in 10 patients	More than 1 in 10 patients		More than 1 in 10 patients
Abdominal pain				More than 1 in 10 patients	More than 1 in 10 patients
Oedema (fluid retention eg swollen ankles)	More than 1 in 10 patients	More than 1 in 10 patients			
Pleural effusion (fluid around the lungs)		More than 1 in 10 patients			
Blocked arteries					More than 1 in 10 patients
Abnormal liver function test results	More than 1 in 10 patients		More than half of all patients	More than half of all patients	More than 1 in 10 patients
Raised glucose levels			More than 1 in 10 patients		
Anaemia	More than half of all patients	More than half of all patients	More than 1 in 10 patients	More than half of all patients	
Neutropenia (low white blood cells)	More than half of all patients	More than 1 in 10 patients	More than 1 in 10 patients	More than 1 in 10 patients	More than 1 in 10 patients
Low platelets/abnormal platelet function	More than half of all patients	More than half of all patients		More than 1 in 10 patients	

More than 1 in 10 patients	More than 1 in 10 patients
More than half of all patients	More than half of all patients


How useful are these to patients

- Network Meta-Analysis
 - Assumes consistency $OR_{AB} = OR_{AC} / OR_{BC}$
 - No material differences in treatment effect modifiers
 - Too much information, not patient focused
 - Clear link to underlying studies
- Patient leaflet
 - (Too) concise information, patient focused
 - Assumes naïve indirect comparisons valid
 - No material differences in treatment effect modifiers or prognostic factors
 - No clear link to underlying studies
- Argumentation based synthesis?


Arguments based on trial comparisons ($P < 0.05$) for MMR




Arguments based on trial comparisons for (($P < 0.05$) $P < 0.05$) Diarrhea




Arguments based on trial comparisons for (($P < 0.05$) $P < 0.05$) Diarrhea




Arguments based on trial comparisons for Diarrhea




Comparison of arguments based on trial comparisons for Diarrhea and MMR




Arguments based on NMA and trial comparisons for MMR



Arguments based on NMA for MMR and Diarrhea



Arguments based on NMA for MMR and Nausea



Next Steps

- Indicate magnitude of effects to allow patients to make trade-offs
- Interactive app to allow patients to focus on what matters to them